Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024

被引：21

作者：

Maurel, Marine ^{[1
]}

Howard, Jennifer ^{[1
]}

Kissling, Esther ^{[1
]}

Pozo, Francisco ^{[2
,3
]}

Perez-Gimeno, Gloria ^{[2
,3
,4
]}

Buda, Silke ^{[5
,6
]}

Seve, Noemie ^{[5
]}

McK-enna, Adele ^{[7
]}

Meijer, Adam ^{[8
]}

Rodrigues, Ana Paula ^{[9
]}

Martinez-Baz, Ivan ^{[10
]}

Mlinaric, Ivan ^{[11
]}

Latorre-Margalef, Neus ^{[12
]}

Turi, Gergo ^{[13
]}

Lazar, Mihaela ^{[14
]}

Mazagatos, Clara ^{[2
,3
,4
]}

Echeverria, Aitziber ^{[9
]}

Abela, Stephen ^{[15
]}

Bourgeois, Marc ^{[16
]}

Machado, Ausenda ^{[9
]}

Duerrwald, Ralf ^{[17
]}

Petrovic, Goranka ^{[10
]}

Oroszi, Beatrix ^{[13
]}

Jancoriene, Ligita ^{[15
,18
]}

Marin, Alexandru ^{[19
]}

Husa, Petr ^{[20
,21
]}

Duffy, Roisin ^{[7
]}

Dijkstra, Frederika ^{[8
]}

Garcia, Virtudes Gallardo ^{[22
]}

Goerlitz, Luise ^{[4
]}

Enouf, Vincent ^{[23
]}

Bennett, Charlene ^{[24
]}

Hooiveld, Mariette ^{[25
]}

Guiomar, Raquel ^{[26
]}

Trobajo-Sanmartin, Camino ^{[10
]}

Vucina, Vesna Visekruna ^{[11
]}

Hagey, Tove Samuelsson ^{[12
]}

Azevedo, Ana Sofia Lameiras ^{[27
]}

Castilla, Jesus ^{[10
]}

Xuereb, Gerd ^{[15
,28
]}

Delaere, Benedicte ^{[16
]}

Gomez, Veronica ^{[9
]}

Tolksdorf, Kristin ^{[5
]}

Bacci, Sabrina ^{[29
]}

Nicolay, Nathalie ^{[29
]}

Kaczmarek, Marlena ^{[29
]}

MC Rose, Angela ^{[1
]}

机构：

[1] Epiconcept, Paris, France

[2] Inst Hlth Carlos III, WHO Natl Influenza Ctr, Natl Ctr Microbiol, Natl Influenza Reference Lab, Madrid, Spain

[3] Inst Hlth Carlos III, CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain

[4] Inst Hlth Carlos III, Natl Ctr Epidemiol, Madrid, Spain

[5] Robert Koch Inst, Dept Infect Dis Epidemiol, Resp Infect Unit, Berlin, Germany

[6] Sorbonne Univ, Inst Pierre Louis epidemiol & St Publ IPLESP UMRS, INSERM, Paris, France

[7] HSE Hlth Protect Surveillance Ctr, Dublin, Ireland

[8] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Bilthoven, Netherlands

[9] Inst Nacl Saude Doutor Ricardo Jorge, Epidemiol Dept, Lisbon, Portugal

[10] Inst Salud Publ Navarra IdiSNA, CIBERESP, Pamplona, Spain

[11] Croatian Inst Publ Hlth, Zagreb, Croatia

[12] Publ Hlth Agcy Sweden, Stockholm, Sweden

[13] Semmelweis Univ, Epidemiol & Surveillance Ctr, Natl Lab Hlth Secur, Budapest, Hungary

[14] Cantacuzino Natl Mil Med Inst Res & Dev, Bucharest, Romania

[15] Hlth Promot & Dis Prevent, Infect Dis Prevent & Control Unit IDCU, Msida, Malta

[16] Catholic Univ Louvain, Dept Infect Dis, CHU UCL Namur Site Godinne, Yvoir, Belgium

[17] Robert Koch Inst, Natl Reference Ctr Influenza, Berlin, Germany

[18] Vilnius Univ, Inst Clin Med, Med Fac, Clin Infect Dis & Dermatovenerol, Vilnius, Lithuania

[19] Dr Victor Babes Clin Hosp Infect & Trop Dis, Bucharest, Romania

[20] Univ Hosp Brno, Brno, Czech Republic

[21] Masaryk Univ, Brno, Czech Republic

[22] Consejeria Salud & Consumo, Serv Vigilancia & Salud Laboral, Direcc Gen Salud Publ & Ordenac Farmaceut, Andalucia, Spain

[23] Univ Paris Cite, Ctr Natl Reference Virus Infect Respiratoire CNR, Inst Pasteur, Paris, France

[24] Univ Coll Dublin, Natl Virus Reference Lab, Dublin, Ireland

[25] Nivel, Utrecht, Netherlands

[26] Inst Nacl Saude Doutor Ricardo Jorge, Lab Nacl Referencia Gripe & Outros Virus Resp, Lisbon, Portugal

[27] Direcc Gen Salud publ, Serv Vigilancia & Control Epidemiol, Subdirecc Gen Epidemiol & Vigilancia Salud, Valencia, Spain

[28] Mater Dei Hosp, Dept Child & Adolescent Hlth, Msida, Malta

[29] European Ctr Dis Prevent & Control, Stockholm, Sweden

来源：

EUROSURVEILLANCE | 2024年 / 29卷 / 08期

关键词：

D O I：

10.2807/1560-7917.ES.2024.29.8.2400089

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU -PC) and hospital (EU -H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU -PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU -H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.

引用

页数：8

共 13 条

[1] Covenay J, 2015, FIRTHLOGIT STATA MOD
[2] ECDC, Vaccine Scheduler | ECDC Internet
[3] European Centre for Disease Prevention and Control, 2023, ) Core Protocol for ECDC Studies of Vaccine Effectiveness against Symptomatic Laboratory-Confirmed Influenza or SARS-CoV-2 infection at Primary Care Level: Version 1.0
[4] European Centre for Disease Prevention and Control (ECDC), 2024, Influenza virus characterization-Summary Europe
[5] European Centre for Disease Prevention and Control (ECDC), 2023, COR PROT ECDC VEBIS
[6] European Centre for Disease Prevention and Control (ECDC), 2023, INFL VIR CHAR SUMM E
[7] European Centre for Disease Prevention and Control (ECDC), 2024, European Respiratory Virus Surveillance Summary (ERVISS)
[8] Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study
Maurel, Marine
Pozo, Francisco
Perez-Gimeno, Gloria
Buda, Silke
Seve, Noemie
Oroszi, Beatrix
Hooiveld, Mariette
Gomez, Veronica
Domegan, Lisa
Martinez-Baz, Ivan
Ilic, Maja
Carnahan, Anna Sara
Mihai, Maria Elena
Martinez, Ana
Goerlitz, Luise
Enouf, Vincent
Horvath, Judit Krisztina
Dijkstra, Frederika
Rodrigues, Ana Paula
Bennett, Charlene
Trobajo-Sanmartin, Camino
Mlinaric, Ivan
Latorre-Margalef, Neus
Ivanciuc, Alina
Lopez, Aurora
Duerrwald, Ralf
Falchi, Alessandra
Turi, Gergo
Meijer, Adam
Melo, Aryse
O'Donnell, Joan
Castilla, Jesus
Vucina, Vesna Visekruna
Hagey, Tove Samuelsson
Lazar, Mihaela
Kaczmarek, Marlena
Bacci, Sabrina
Kissling, Esther
[J]. INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (01)
[9] NASA Earth Observatory, 2023, 2023 Fire season in the northern hemisphere
[10] Rose AMC, 2024, INFLUENZA OTHER RESP, V18, DOI 10.1111/irv.13255

← 1 2 →